Clinical trial · Interventional
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma
NCT03161379CI-TRIAL-00085396completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| GVAX Pancreas Vaccine | Drug | — | UNRESOLVED |
| Nivolumab | Drug | Nivolumab | ALIAS |
| Stereotactic Body Radiation (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CY, Nivolumab, GVAX, and SBRT
- description
- CY, Nivolumab, GVAX, and SBRT
- interventionNames
- Drug: Cyclophosphamide
- Drug: Nivolumab
- Drug: GVAX Pancreas Vaccine
- Radiation: Stereotactic Body Radiation (SBRT)
Primary outcomes (1)
- measure
- CD8+ T Cell Density in Tumor Tissue
- timeFrame
- evaluated at time of surgery, approximately 2 months from first dose of study drug
- description
- Mean CD8+ T cell density \[log(cells per mm\^2)\], found in resected surgical tissue by Immunohistochemistry (IHC).
Secondary outcomes (1)
- measure
- Pathologic Complete Response (pCR) Rate at Surgical Resection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have histologically proven pancreatic cancer that is borderline resectable * No more than 1 month/cycle (28 days) of systemic therapy for pancreatic cancer * Age \>18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Patients must have adequate organ and marrow function defined by study-specified laboratory tests. * Woman of child bearing potential must have a negative pregnancy test. * Must use an acceptable form of birth control while on study. * Must be candidate for Stereotactic Body Radiation Therapy (SBRT) * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Had major surgery within the last 28 days * Had an investigational drug or device within the past 28 days * Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc) * Completed more than 1 month/cycle (28 days) of chemotherapy for pancreas cancer * Patient on an immunosuppressive systemic treatment, such as steroids, in the past 2 years. * Other cancer diagnosis requiring treatment within two years * History of allergic reactions related to the drugs (Nivolumab, Cyclophosphamide, GM-hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin), yeast or any other component of the GVAX vaccine) in this study. * Patients receiving growth factors within the last 14 days. * Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, psychological, immune or other medical conditions. * Pregnant or breastfeeding. * Have known history of infection with HIV, hepatitis B, or hepatitis C. * Unwilling or unable to follow the study schedule for any reason. * Presence of tissue or organ allograft, regardless of need for immunosuppression (including corneal allograft) * Squamous pancreatic cancer or adenosquamous pancreatic cancer with malignant squamous cells \>30%
References
Publications (0)
Data not yet available
No reference posted for this study.